3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1/2
3
Phase 2
2
Phase 1
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Melanoma
55
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasms
14
Pancreatic Neoplasms
11
Uveal Melanoma
10
Prostatic Neoplasms
10
Leukemia, Myeloid, Acute
9
Squamous Cell Carcinoma of Head and Neck
7
Sarcoma
7
Myelodysplastic Syndromes
7
Lymphoma
7
Lung Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Recurrence
5
Myeloproliferative Disorders
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Glioblastoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Interventions
pembrolizumab
28
Cisplatin
24
Oxaliplatin
22
Irinotecan
22
Fluorouracil
22
Capecitabine
20
Leucovorin
17
Paclitaxel
16
Cyclophosphamide
14
Trastuzumab
12
Nivolumab
11
Carboplatin
11
Gemcitabine
10
Bevacizumab
10
Docetaxel
9
fludarabine
8
aldesleukin
8
S 1 (combination)
8
Ramucirumab
7
130-nm albumin-bound paclitaxel
7
atezolizumab
6
Albumin-Bound Paclitaxel
6
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
veliparib
4
tislelizumab
4
spartalizumab
4
dehydroftorafur
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Stomach Neoplasms
×
Ipilimumab
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled
NCT03784040
2019-04-08
da VINci
National University Hospital, Singapore
Phase 1
Unknown
40 enrolled